GSK (GSK) has agreed to acquire oncology company IDRx for up to $1.15 billion, the companies said Monday.
The consideration includes $1 billion in an upfront payment, and up to $150 million in potential regulatory-based milestone payments. GSK will also be responsible for milestone and royalty payments owed to Merck KGaA related to IDRX-42, a treatment candidate for gastrointestinal stromal tumors.
The deal is subject to regulatory clearances, and other customary conditions.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。